Gene mutation-targeted agents like FLT3 and IDH inhibitors have shown promise in AML (6, 7), and a combinatory immunotherapy comprising histamine dihydrochloride and interleukin-2 (HDC/IL-2) is approved for relapse prevention for AML in the European Union (8). The gene discussed is IL2; the disease is acute myeloid leukemia.